2012
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
Nicholas J, Morgan-Followell B, Pitt D, Racke MK, Boster A. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. Journal Of Central Nervous System Disease 2012, 4: jcnsd.s6692. PMID: 23650470, PMCID: PMC3619700, DOI: 10.4137/jcnsd.s6692.Peer-Reviewed Original ResearchMultiple sclerosisRelapsing-remitting multiple sclerosisKey clinical trialsDisease-Modifying TherapiesMonoclonal antibody therapyIFN β-1aIFN-β-1bMS includingAvailable efficacyOral agentsGlatiramer acetateTreatment algorithmAntibody therapyClinical trialsPromising therapySafety dataNew therapiesTherapyNew FDATherapeutic landscapeActive investigationNatalizumabFingolimodSclerosisFDA
2011
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
Boster A, Bartoszek MP, O’Connell C, Pitt D, Racke M. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis. Therapeutic Advances In Neurological Disorders 2011, 4: 319-332. PMID: 22010043, PMCID: PMC3187678, DOI: 10.1177/1756285611422108.Peer-Reviewed Original Research